WUH: Prose: A prospective Observational study of adult patients receiving Dupixent for Atopic Dermatitis

Brief description of study

This study is conducted to observe the real-world patient characteristics, use, effectiveness and safety of the drug DUPIXENT, also known as dupilumab by its generic name. DUPIXENT is approved by the Food and Drugs Administration (FDA) for the treatment of moderate to severe atopic dermatitis (AD), commonly known as eczema. The main purpose of this study is to collect long-term data on adolescent and adult patients with moderate to severe atopic dermatitis who received treatment with DUPIXENT.

Clinical Study Identifier: s18-01441
ClinicalTrials.gov Identifier: NCT03428646
Principal Investigator: Luz S Fonacier.
Other Investigator: Erin Michelle Banta.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.